Your session is about to expire
← Back to Search
Decitabine for Pancreatic Cancer
Study Summary
This trial is testing a new cancer treatment combining Decitabine with Gemcitabine to see if it is safe and effective.
- Pancreatic Cancer
- Sarcoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 14 Patients • NCT04055844Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are engaging in this research project?
"At the moment, this medical research is not actively seeking new participants. Initially posted on December 1st 2016 and last updated on August 21th 2022, it has been concluded for now. However, there are 1234 sarcoma studies presently recruiting as well as 547 Decitabine clinical trials that may be of interest to explore."
What medical conditions has Decitabine been known to address?
"Decitabine is commonly used to treat refractory anemia, as well as urinary bladder cancer, intermediate-2 risk category ipss and small cell lung carcinoma (sclc)."
What safety profile does Decitabine possess?
"Limited data exists in regards to Decitabine's safety and efficacy, causing the medication to be assigned a score of 1."
Are there any precedential investigations that have featured Decitabine?
"Currently, 547 clinical trials for Decitabine are underway with 149 in Phase 3. Numerous sites scattered across the world, including Woolloongabba Queensland, are running these studies; all together there are 26047 such locations."
Are there remaining availabilities for participants in this research?
"According to clinicaltrials.gov, this medical trial is not currently in the process of enrolling patients. Initially posted on December 1st 2016 and last updated August 21st 2022, it is no longer recruiting; however there are 1781 other studies that remain actively seeking participants."
Share this study with friends
Copy Link
Messenger